PATENT CLAIM ANALYSIS

Application Number: 15892265
Application Type: Utility
Filing Date: 2018-02
Publication Date: 2018-09
Patent Classification: ["424", "093210"]

Abstract:
Embodiments of the invention are directed methods that include a thymidine kinase deficient vaccinia virus. The methods include administering the vaccinia virus at increased viral concentrations. Further aspects of the invention include methods for inducing oncolysis or collapse of tumor vasculature in a subject having a tumor comprising administering to a subject at least 1×10 8  infectious viral particles of a TK-deficient, GM-CSF-expressing, replication-competent vaccinia virus vector sufficient to induce oncolysis of cells in the tumor.

Claim (Index 13):
The method of  claim 1 , further comprising assessing tumor cell viability following treatment.

Metadata:
- Claim Count in Document: 50.0
- Percentile: 88.0
- Lexical Diversity: 1.65306
- Patent Class: 424.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['13535291', '14656397', '14876195', '11470951', '15892247']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7017502458553346
- 35 USC 102 Novelty (BERT): 0.5987801509729141
- Combined Prediction Score: 0.6914532363670925
- Mean Citation Score: 493.250046
- Max Citation Score: 541.0012
- Similarity Product: 441.72251827309134

Labels:
- Claim Label 101: 0
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 0
- Label 101 Adjusted: 0

Dataset: test